The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s disease  with motor fluctuations. We have led the clinical trial in Spain with this drug. Our patients are continuing to use it during the open label extension.

Compartir:

No dude en llamarnos        1-+34 935 656 000